Isturisa® continues to show promise in Cushing’s disease
New Phase III trial results show 81 percent of Cushing’s…
New Phase III trial results show 81 percent of Cushing’s disease patients who received Isturisa® (osilodrostat) had sustained normalisation of mean urinary free cortisol levels.